Kenealy M - Search Results

1

Treatment-related myelodysplasia following fludarabine combination chemotherapy.

Tam CS, Seymour JF, Prince HM, Kenealy M, Wolf M, Januszewicz EH, Westerman D. Tam CS, et al. Among authors: kenealy m. Haematologica. 2006 Nov;91(11):1546-50. Haematologica. 2006. PMID: 17082012

2

Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma.

Kenealy MK, Prince HM, Hönemann D. Kenealy MK, et al. Pharmacotherapy. 2006 Aug;26(8):1205-6; discussion 1206. doi: 10.1592/phco.26.8.1205. Pharmacotherapy. 2006. PMID: 16863501 No abstract available.

3

Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.

Lane SW, Crawford J, Kenealy M, Cull G, Seymour JF, Prince HM, Marlton P, Gill D, Mollee PN. Lane SW, et al. Among authors: kenealy m. Leuk Lymphoma. 2006 Sep;47(9):1813-7. doi: 10.1080/10428190600632832. Leuk Lymphoma. 2006. PMID: 17064993

4

Current status of new drugs for the treatment of patients with multiple myeloma.

Kenealy M, Prince HM. Kenealy M, et al. Intern Med J. 2006 Dec;36(12):781-9. doi: 10.1111/j.1445-5994.2006.01218.x. Intern Med J. 2006. PMID: 17096741 Review.

5

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.

Bishton M, Kenealy M, Johnstone R, Rasheed W, Prince HM. Bishton M, et al. Among authors: kenealy m. Expert Rev Anticancer Ther. 2007 Oct;7(10):1439-49. doi: 10.1586/14737140.7.10.1439. Expert Rev Anticancer Ther. 2007. PMID: 17944568 Review.

6

Carney DA, Westerman DA, Tam CS, Milner A, Prince HM, Kenealy M, Wolf M, Januszewicz EH, Ritchie D, Came N, Seymour JF. Carney DA, et al. Among authors: kenealy m. Leukemia. 2010 Dec;24(12):2056-62. doi: 10.1038/leu.2010.218. Epub 2010 Oct 21. Leukemia. 2010. PMID: 20962860

7

Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.

Gangatharan SA, Carney DA, Campbell LJ, Prince HM, Kenealy MK, Seymour JF. Gangatharan SA, et al. Eur J Haematol. 2011 Aug;87(2):186-8. doi: 10.1111/j.1600-0609.2011.01653.x. Eur J Haematol. 2011. PMID: 21623918 No abstract available.

8

When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?

Bird RJ, Kenealy M, Forsyth C, Wellwood J, Leahy MF, Seymour JF, To LB. Bird RJ, et al. Among authors: kenealy m. Intern Med J. 2012 Apr;42(4):450-5. doi: 10.1111/j.1445-5994.2012.02734.x. Intern Med J. 2012. PMID: 22498118

9

Treatment of chronic myelomonocytic leukemia with azacitidine.

Wong E, Seymour JF, Kenealy M, Westerman D, Herbert K, Dickinson M. Wong E, et al. Among authors: kenealy m. Leuk Lymphoma. 2013 Apr;54(4):878-80. doi: 10.3109/10428194.2012.730615. Epub 2012 Oct 5. Leuk Lymphoma. 2013. PMID: 22988826 No abstract available.

10

Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).

Kenealy M, Patton N, Filshie R, Nicol A, Ho SJ, Hertzberg M, Mills T, Prosser I, Link E, Cowan L, Zannino D, Seymour JF. Kenealy M, et al. Leuk Lymphoma. 2017 Feb;58(2):298-307. doi: 10.1080/10428194.2016.1190971. Epub 2016 Jun 7. Leuk Lymphoma. 2017. PMID: 27268068 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters